Introduction Our objective was to systematically review and analyze published data on bone mineral density (BMD) and fracture rates in patients with phenylketonuria (PKU), and relationships between BMD and phenylalanine levels. Methodology We searched PubMed, CINAHL, and Cochrane databases from January 1966 to November 2013 for studies of spine BMD or fracture in PKU and control subjects. We excluded studies assessing skeletal health by ultrasound or peripheral quantitative computer tomography. Both authors reviewed abstracts for inclusion, and read full text papers to extract data. Results Sixteen studies met eligibility criteria. Meta-analysis of three studies found that spine BMD was 0.100 g/cm 2 lower (95% CI, -0.110, -0.090 g/cm 2 ) in 67 subjects with PKU, compared to 161 controls. Among six studies, 20% (53 of 263) of PKU subjects experienced clinical fractures. In the single study with controls, the fracture rate was 2.6 fold higher (95% CI, 1.1-6.1) after age 8 in PKU subjects, compared to healthy sibling controls. When considering a total of 12 studies in 412 subjects, nine or 75% of studies representing 71% of studied subjects reported no association between phenylalanine levels and BMD. Summary Spine BMD is lower in PKU than control subjects, but only one study controlled for smaller body size. Existing studies suggest a clinical fracture rate of 20% among PKU subjects, but fracture rates in controls are lacking. Finally, existing data shows no consistent relationship between phenylalanine levels and BMD. Future studies are needed to clarify the etiology and health consequences of low BMD in PKU.
Introduction
Phenylketonuria (PKU, OMIM 262600) is an autosomal recessive genetic disorder caused by reduced activity of hepatic phenylalanine hydroxylase (PAH, EC 1.14.16.1), preventing conversion of phenylalanine to tyrosine and resulting in elevated blood phenylalanine concentration with a typical diet (Vockley et al. 2014) . The disease was first described in 1934 (Fölling 1934) , but low-phenylalanine medical foods were not developed until 1953 (Bickel et al. 1953) . In 1965, widespread neonatal screening for PKU allowed diagnosis and prescription of low-phenylalanine medical formula within days of birth, to prevent or mitigate devastating neurologic sequela of PKU including seizures and cognitive impairment.
As the first children diagnosed through newborn screening tests in the 1960s reach their late 40s, studies have described low bone mineral density (BMD) as part of the disorder. It is the purpose of this paper to summarize existing literature describing BMD and fracture rates in patients with PKU, and the association between serum phenylalanine levels and BMD. We conclude by suggesting potential directions for future research on causes of low BMD in patients with PKU.
Materials and methods
We conducted this study using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (Moher et al. 2009 ). The primary study outcomes were spine BMD measurements and fracture rates in subjects with PKU, compared to these measures in age and gender-matched controls. The secondary outcome was the relationship between serum or plasma phenylalanine levels and spine BMD in subjects with PKU.
Eligible studies measured spine BMD via dual energy Xray absorptiometry (DXA) or reported fractures in children or adults with PKU. BMD studies were only included when researchers also measured BMD in age and gender matched controls. We included studies written in any language. We excluded studies in which skeletal health was assessed by ultrasound or peripheral quantitative computer tomography, as normative data for these measures are not available. Additionally, the International Society for Clinical Densitometry recommends spine and total body (less head) measurements to assess BMD in children (Gordon et al. 2008) . We also excluded in vitro and murine studies.
To identify relevant articles, we searched PubMed, CINAHL, and Cochrane databases from January 1, 1966 to November 18, 2013. We crossed the search term "phenylketonuria" with "bone mineral density," "osteoporosis" and "fractures". No limitations were applied to the searches. Two authors read all abstracts to determine eligibility for inclusion (level 1 review). Articles appearing to meet inclusion criteria underwent full text review by two authors (level 2 review). During level 3 review, data were extracted into tables by one author. The second author confirmed data extraction was accurate. Disagreement was resolved by consensus. The bibliographies of all level 3 publications were reviewed to identify additional studies for inclusion.
There was no independent funding for this project. The study review protocol was developed by both authors but was not registered or described on the web.
Data analysis
We compared spine BMD (g/cm 2 ) in subjects with and without PKU by Forest plot, using R software (version 3.0.2) and the package "meta" (R Core Development Team 2008). Heterogeneity between studies was assessed primarily by inspection of Forest plots and the I 2 statistic, with 25%, 50%, and 75% indicating low, moderate, and high heterogeneity (Higgins et al. 2003) . Funnel plots (scatterplots of effect versus study size) were reviewed to detect publication bias. We used descriptive statistics to summarize fracture studies, and studies reporting associations between serum or plasma phenylalanine levels and BMD.
Results
Fifty-two citations were identified from the electronic search and review of bibliographies. From 52 citations undergoing level 1 review (title and abstract), 21 articles underwent level 2 review (full text), leading to identification of 16 studies for level 3 review and inclusion. Figure 1 (online supplemental material) summarizes the studies identified and reasons for exclusion.
Bone mineral density in PKU Three studies (Allen et al. 1994; Hillman et al. 1996; Koura et al. 2011) reported spine BMD in 67 individuals with PKU and 161 healthy age and gender matched controls (Table 1) . A Forest plot of these three studies (Fig. 2 ) demonstrated that spine BMD was 0.100 g/cm 2 lower (95% CI, -0.110, -0.090 g/cm 2 ) in subjects with PKU, compared to controls. No significant heterogeneity was detected between studies (I 2 =0%). Reduced body size is a potential confounder when measuring BMD. Two-dimensional measurements of the skeleton via DXA can underestimate BMD in shorter individuals and overestimate BMD in tall individuals (Zhang et al. 2012) , since DXA measurements do not fully account for body size. All three BMD studies reported weight in PKU and control subjects, but only two studies reported height. Of note, weight was lower by 4.53 kg (95% CI, -5.58 to -3.48) in PKU compared to control subjects (n=3 studies, I 2 =0%). Additionally, height was lower by 6.47 cm (95% CI, -8.10 to -4.84) in PKU compared to control subjects (n=2 studies, I 2 =0%, Only one study adjusted BMD data for height. In that study (Allen et al. 1994) , spine BMD was still lower after controlling for the shorter height of PKU subjects, compared to controls (0.637±0.075 g/cm 2 in PKU, 0.692±0.062 g/cm 2 in controls, p=0.003).
Fractures in PKU
Six studies (Carson et al. 1990; Greeves et al. 1997; PerezDuenas et al. 2002; Modan-Moses et al. 2007; Porta et al. 2008; Porta et al. 2011) reported fracture rates in 263 PKU subjects (Table 2) . Only one study (Greeves et al. 1997) reported fractures in a group of controls. All fractures were based on a clinical diagnosis; no studies used spine radiographs to detect asymptomatic vertebral fractures. Three of six studies reported the circumstances leading to fractures (e.g., high trauma).
Among the six studies, 53 of 263 subjects with PKU experienced clinical fractures, suggesting a fracture rate of 20% in children with PKU. In the single study (Greeves et al. 1997 ) using a control arm, clinical fractures occurred in 21 of 85 PKU subjects (25%), and 18 of 98 healthy sibling controls (18%). In that study, the fracture rate was 2.6 fold higher (95% CI, 1.1 to 6.1) after age 8 in subjects with PKU, compared to healthy sibling controls. Authors suggested that increased consumption of phenylalanine might account for the higher rate of fractures after age 8, as historically children with PKU were permitted to liberalize their diet after this age.
Relationship between bone mineral density and serum phenylalanine Twelve studies (McMurry et al. 1992; Allen et al. 1994; Hillman et al. 1996; Al-Qadreh et al. 1998; Barat et al. 2002; Perez-Duenas et al. 2002; Millet et al. 2005; ModanMoses et al. 2007; Adamczyk et al. 2010; Lage et al. 2010; Koura et al. 2011; de Groot et al. 2012) in 412 PKU patients evaluated correlations between BMD and phenylalanine levels ( Table 3) . Three of 12 studies (McMurry et al. 1992; Al-Qadreh et al. 1998; Adamczyk et al. 2010 ) in 119 of 412 (29%) PKU patients reported an inverse association between phenylalanine and BMD. One study reported the correlation , p "NS") but spine Z-score lower in those with PKU (-0.4±0.12 vs. 0.1±0.11, p=0.01). Allen, 1994 Koura, 2011 Hillman, 1996 coefficient and p-value for the observed association. The remaining nine studies in 293 PKU patients found no association between phenylalanine levels and BMD. Among the nine studies, only one reported the correlation coefficient and p-value for study data. Since only two of 12 studies reported correlation coefficients and p-values, a meta-analysis of all 12 studies was not possible. In summary, 75% of studies representing 71% of studied subjects reported no association phenylalanine and BMD.
PKU Controls Mean Difference [95% CI] Study

Assessment of publication bias
We generated funnel plots, or scatterplots of standard error (vertical axis) versus mean difference between subjects and controls (horizontal axis), to detect potential publication bias. Plots suggested low publication bias with respect to spine BMD, height, weight, and height Z-score. The one exception was the funnel plot for weight Z-score, which did suggest a significant publication bias. However, only two studies reported subjects' weight Z-score (Allen et al. 1994; Koura et al. 2011 ) and the larger study was the one that appeared biased, emphasizing the need for more data on weight Z-score in PKU patients.
Discussion
We performed a systematic review of literature describing spine BMD and fracture rates in patients with PKU. Metaanalysis confirmed that spine BMD was significantly lower in individuals with PKU, compared to age and gender matched controls. However, only one study corrected for the reduced height of PKU subjects. Although authors still found that BMD was lower in PKU subjects, experts acknowledge that measurement of BMD in short individuals can underestimate BMD. Future studies of BMD in PKU subjects should correct measurements for height, using published equations developed for this purpose (Zhang et al. 2012 ).
PKU Controls
Study n M e a n SD n M e a n SD We identified six studies reporting fractures in subjects with PKU. Together these studies suggest a clinical fracture rate of ∼20%, but regrettably only one study also determined fracture rates in healthy controls. Compared to healthy sibling controls, children with PKU had more fractures, particularly after age 8 when historically, intake of phenylalanine was liberalized. The study therefore suggested that higher phenylalanine levels might be the cause of low BMD in patients with PKU. However, scrutiny of 12 studies representing 412 individuals with PKU detected no consistent relationship between high phenylalanine levels and lower BMD.
It is noteworthy that the study reporting the highest percent of PKU patients with fractures (Carson et al. 1990 ) recruited individuals who were likely born in the 1960s. By contrast, the other fracture studies (Table 2 ) included children born in the 1980s and 1990s. Since lifelong strict dietary adherence was recommended by the year 2000 for all PKU patients (2001), suggesting that high phe levels might be responsible for low BMD and higher fracture rates. However, we found no consistent association between phe and BMD, regardless of the decade of birth (Table 3) . We therefore suspect that the higher fracture rate in the Carson study might be due to the older age of the participants, leading to greater chances to experience events contributing to fractures.
To our knowledge, this is the first systematic review and meta-analysis on BMD and fractures in subjects with PKU. Our study has several strengths. We limited our analysis to measures of spine BMD, as the International Society for Clinical Densitometry (Gordon et al. 2008 ) states spine BMD is one of two reliable indicators of skeletal status in children. Two authors reviewed all abstracts to determine eligibility for inclusion of each study and performed duplicate data extraction; disagreements were resolved by consensus.
Our study also has a number of limitations. Only one study measured whole body BMD, precluding meta-analysis of this additional measure of skeletal health. Fractures were based on clinical diagnosis. No studies used spine imaging to detect silent vertebral fractures, the hallmark of skeletal fragility. Several studies assessing relationships between phenylalanine levels and BMD relied on a single phenylalanine level. However, two of the three studies reporting an inverse correlation between phenylalanine levels and BMD used multiple phenylalanine levels collected over 6-12 months. Finally, we found no publications linking BMD values to subsequent risks of fracture.
Additional well-designed, long-term prospective research studies are recommended in individuals with PKU, to evaluate skeletal health. We recommend that such studies measure spine and total body BMD and bone mineral content (Barat et al. 2002) n=1 3m e d i a n1 2 , range 5-21
Age 1 month to time of BMD test, method not reported Phenylalanine levels similar in subjects with spine Z-score<-1 (n=8) and Z-score≥-1 (n=5), R & p value not reported Netherlands (de Groot et al. 2012) n=53 17±9 Every 2-4 weeks for one year, high performance liquid chromatography
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